WO2022224193 - BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE
National phase entry:
Publication Number
WO/2022/224193
Publication Date
27.10.2022
International Application No.
PCT/IB2022/053744
International Filing Date
21.04.2022
Title **
[English]
BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE
[French]
THÉRAPIE BACTÉRIOPHAGE CONTRE ESCHERICHIA COLI NON INVASIF
Applicants **
FERRING B.V.
Inventors
WANNERBERGER, Kristin
SULAKVELIDZE, Alexander
Priority Data
63/178,119
22.04.2021
US
63/203,560
27.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3085 | |
| EPO | Filing, Examination, Granting | 23634 | |
| Japan | Filing, Examination, Granting | 3051 | |
| South Korea | Filing, Examination, Granting | 3928 | |
| USA | Filing, Examination, Granting | 14340 |
Total:
48,038
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
(AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.[French]
(AIEC) non invasif. Les bactériophages sont utiles, par exemple, pour le traitement prophylactique ou thérapeutique de sujets infectés par AIEC ou à risque d'infection par AIEC, ou dans le traitement prophylactique ou thérapeutique de maladies et d'états associés à l'AIEC, y compris la maladie intestinale inflammatoire (IBD), l'infection des voies urinaires (UTI), la méningite néonatale, l'asthme, la bronchopneumopathie chronique obstructive (BPCO), la bronchite, la pneumonie et le cancer du poumon, chez un sujet dans et pour d'autres utilisations décrites dans la description.